1					2					3			4
		5					6
												7
8
														9										10
											11									12
13													14
																	15
	16							17
18																						19
20		21
22								23		24
												25
																			26
												27

Across 3. Phase following a tonic-clonic seizure 7. Antiepileptic drug which requires no therapeutic monitoring; brand name 8. Treated with mannitol when increased; normal 0-15mm Hg 11. Neurotransmitter deficit found in Parkinson's disease 13. Temporary loss of reflex, bradycardia, hypotension, flaccid paralysis 15. Initial treatment to reduce edema in SCI 16. MAP minus ICP equals this perfusion pressure; normal is 18. Exaggerated sympathetic response in T6 or higher spinal cord injury 21. Used to treat MS 22. Widening pulse pressure, bradycardia, irregular respirations; late sign increased ICP 25. Flexor posturing; Problems with cervical spinal tract or cerebral hemisphere 26. Most common TBI 27. "Daydreaming" seizure

Down 1. Upper and lower extremity paralysis 2. Osmotic diuretic 4. Mini stroke 5. Series of seizures lasting 30 min. or longer 6. Antiepileptic with therapeutic level of 10-20mcg/ml; brand name 9. Short, shuffling; associated with PD 10. Drainage from ears or nose will test positive for this if CSF 12. Type of CVA caused by an aneurysm 14. Extensor posturing; Problems within midbrain or pons 17. Change in this is most significant sign of increased ICP 19. Edematous optic disc on retinal exam; Increased ICP sign 20. Position after a seizure 23. PD drug; monitor for dyskinesia uncontrolled movements of arms, legs, tongue,face, eyelids 24. Pharmacologic intervention used for thrombotic or embolic CVA